RS7 antibodies
    2.
    发明授权
    RS7 antibodies 有权
    RS7抗体

    公开(公告)号:US07238785B2

    公开(公告)日:2007-07-03

    申请号:US10377121

    申请日:2003-03-03

    摘要: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

    摘要翻译: 本发明涉及单价和多价单特异性结合蛋白和多价多特异性结合蛋白。 这些结合蛋白的一个实施方案具有一个或多个结合位点,其中每个结合位点与靶抗原或靶抗原上的表位结合。 这些结合蛋白的另一个实施方案具有两个或多个结合位点,其中每个结合位点对靶抗原上的不同表位具有亲和力,或对靶抗原或半抗原具有亲和力。 本发明还涉及可用于在宿主中表达这些功能性结合蛋白的重组载体。 更具体地,本发明涉及称为RS7的肿瘤相关抗原结合蛋白和其它EGP-1结合蛋白。 本发明还涉及人源化,人和嵌合RS7抗原结合蛋白,以及这种结合蛋白在诊断和治疗中的用途。

    RS7 antibodies
    3.
    发明授权
    RS7 antibodies 有权
    RS7抗体

    公开(公告)号:US07517964B2

    公开(公告)日:2009-04-14

    申请号:US11745896

    申请日:2007-05-08

    摘要: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

    摘要翻译: 本发明涉及单价和多价单特异性结合蛋白和多价多特异性结合蛋白。 这些结合蛋白的一个实施方案具有一个或多个结合位点,其中每个结合位点与靶抗原或靶抗原上的表位结合。 这些结合蛋白的另一个实施方案具有两个或多个结合位点,其中每个结合位点对靶抗原上的不同表位具有亲和力,或对靶抗原或半抗原具有亲和力。 本发明还涉及可用于在宿主中表达这些功能性结合蛋白的重组载体。 更具体地,本发明涉及称为RS7的肿瘤相关抗原结合蛋白和其它EGP-1结合蛋白。 本发明还涉及人源化,人和嵌合RS7抗原结合蛋白,以及这种结合蛋白在诊断和治疗中的用途。

    RS7 ANTIBODIES
    4.
    发明申请
    RS7 ANTIBODIES 有权
    RS7抗体

    公开(公告)号:US20070212350A1

    公开(公告)日:2007-09-13

    申请号:US11745896

    申请日:2007-05-08

    摘要: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

    摘要翻译: 本发明涉及单价和多价单特异性结合蛋白和多价多特异性结合蛋白。 这些结合蛋白的一个实施方案具有一个或多个结合位点,其中每个结合位点与靶抗原或靶抗原上的表位结合。 这些结合蛋白的另一个实施方案具有两个或更多个结合位点,其中每个结合位点对靶抗原上的不同表位具有亲和力,或对靶抗原或半抗原具有亲和力。 本发明还涉及可用于在宿主中表达这些功能性结合蛋白的重组载体。 更具体地,本发明涉及称为RS7的肿瘤相关抗原结合蛋白和其它EGP-1结合蛋白。 本发明还涉及人源化,人和嵌合RS7抗原结合蛋白,以及这种结合蛋白在诊断和治疗中的用途。

    RS7 ANTIBODIES
    5.
    发明申请
    RS7 ANTIBODIES 有权
    RS7抗体

    公开(公告)号:US20080131363A1

    公开(公告)日:2008-06-05

    申请号:US11868290

    申请日:2007-10-05

    摘要: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

    摘要翻译: 本发明涉及单价和多价单特异性结合蛋白和多价多特异性结合蛋白。 这些结合蛋白的一个实施方案具有一个或多个结合位点,其中每个结合位点与靶抗原或靶抗原上的表位结合。 这些结合蛋白的另一个实施方案具有两个或更多个结合位点,其中每个结合位点对靶抗原上的不同表位具有亲和力,或对靶抗原或半抗原具有亲和力。 本发明还涉及可用于在宿主中表达这些功能性结合蛋白的重组载体。 更具体地,本发明涉及称为RS7的肿瘤相关抗原结合蛋白和其它EGP-1结合蛋白。 本发明还涉及人源化,人和嵌合RS7抗原结合蛋白,以及这种结合蛋白在诊断和治疗中的用途。

    MULTISPECIFIC NONCOVALENT COMPLEXES FOR DELIVERY OF THERAPEUTICS
    9.
    发明申请
    MULTISPECIFIC NONCOVALENT COMPLEXES FOR DELIVERY OF THERAPEUTICS 有权
    用于递送治疗药物的多重非共价复合物

    公开(公告)号:US20070048227A1

    公开(公告)日:2007-03-01

    申请号:US11553814

    申请日:2006-10-27

    IPC分类号: A61K39/00

    摘要: Embodiments of the invention relate to a method for treating target cells, tissues or pathogens in a subject, comprising administering a non-covalently bound complex which comprises a multispecific targeting protein and a hapten-enzyme covalent conjugate, followed by administration of a prodrug that is converted to an active drug by the enzyme. Other embodiments of the invention further relate to kits comprising the non-covalently bound complex or the components to prepare the complex.

    摘要翻译: 本发明的实施方案涉及用于治疗受试者中靶细胞,组织或病原体的方法,包括施用包含多特异性靶向蛋白质和半抗原酶共价缀合物的非共价结合复合物,然后施用前药,其为 通过酶转化为活性药物。 本发明的其它实施方案还涉及包含非共价结合复合物或制备复合物的组分的试剂盒。